Nonadherence to Primary Prophylaxis against Pneumocystis jirovecii Pneumonia

被引:7
作者
Heffelfinger, James D. [1 ]
Voetsch, Andrew C. [1 ]
Nakamura, Glenn V. [1 ]
Sullivan, Patrick S. [2 ]
McNaghten, A. D. [1 ]
Huang, Laurence [3 ,4 ]
机构
[1] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA
[2] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[3] Univ Calif San Francisco, HIV AIDS Div, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Div Pulmonary & Critical Care Med, San Francisco, CA 94143 USA
来源
PLOS ONE | 2009年 / 4卷 / 03期
基金
美国国家卫生研究院;
关键词
ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; CARINII PNEUMONIA; UNITED-STATES; DRUG-USE; ADHERENCE; PATIENT; EPIDEMIOLOGY; BIAS; AIDS;
D O I
10.1371/journal.pone.0005002
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Despite the effectiveness of prophylaxis, Pneumocystis jirovecii pneumonia (PCP) continues to be the most common serious opportunistic infection among HIV-infected persons. We describe factors associated with nonadherence to primary PCP prophylaxis. Methodology/Principal Findings: We used 2000-2004 data from the Supplement to HIV/AIDS Surveillance (SHAS) project, a cross-sectional interview project of HIV-infected persons >= 18 years conducted in 18 states. We limited the analysis to persons who denied having prior PCP, reported having a current prescription to prevent PCP, and answered the question "In the past 30 days, how often were you able to take the PCP medication(s) exactly the way your doctor told you to take them?'' We used multivariable logistic regression to describe factors associated with nonadherence. Of 1,666 subjects prescribed PCP prophylaxis, 305 (18.3%) were nonadherent. Persons were more likely to be nonadherent if they reported using marijuana (adjusted odds ratio [aOR] = 1.6, 95% confidence interval [CI] = 1.1-2.4), non-injection drugs other than marijuana (aOR = 1.5, 95% CI = 1.0-2.1), or injection drugs (aOR = 2.3, 95% CI = 1.3-4.1) in the past year; their mental health was "not good'' for >= 1 day during the past month (aOR = 1.6, 95% CI = 1.2-2.2); their most recent CD4 count was,200 cells/mu L (aOR = 1.6, 95% CI = 1.1-2.2); or taking ART usually (aOR = 9.6, 95% CI = 6.7-13.7) or sometimes/rarely/never (aOR = 18.4, 95% CI = 11.1-30.4), compared with always, as prescribed. Conclusion/Significance: Providers should inquire about and promote strategies to improve adherence to PCP prophylaxis, particularly among persons who use illicit drugs, have mental health issues, and who are not compliant with ART to reduce the occurrence of PCP.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Pneumocystis jirovecii Pneumonia in Children
    Dhingra, Dhulika
    Mandal, Anirban
    Singh, Amitabh
    JOURNAL OF PEDIATRIC INFECTIOUS DISEASES, 2018, 13 (01) : 2 - 9
  • [22] Pneumocystis Jirovecii Prophylaxis in Neurosurgery
    de Lotbiniere-Bassett, Madeleine
    Dhillon, Mannat
    Couillard, Philippe
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2021, 48 (04) : 592 - 593
  • [23] Safety and Effectiveness of Intravenous Pentamidine for Prophylaxis of Pneumocystis jirovecii Pneumonia in Pediatric Hematology/Oncology Patients
    Solodokin, Loriel J.
    Klejmont, Liana M.
    Scipione, Marco R.
    Dubrovskaya, Yanina
    Lighter-Fisher, Jennifer
    Papadopoulos, John
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2016, 38 (06) : E180 - E185
  • [24] Acute generalised exanthematous pustulosis induced by Pneumocystis jirovecii pneumonia prophylaxis with dapsone
    Vas, A.
    Laws, P.
    Marsland, A. M.
    McQuillan, O.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2013, 24 (09) : 745 - 747
  • [25] Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review
    Sierra, Caroline M.
    Daiya, Krishna C.
    PHARMACOTHERAPY, 2022, 42 (11): : 858 - 867
  • [26] Epidemiology of Pneumocystis jirovecii Pneumonia in Venezuela
    María Mercedes Panizo
    Giuseppe Ferrara
    Nataly García
    Xiomara Moreno
    Trina Navas
    Enrique Calderón
    Current Fungal Infection Reports, 2020, 14 : 21 - 28
  • [27] RECIDIVATING PNEUMONIA CAUSED BY PNEUMOCYSTIS JIROVECII
    Vicente Salvador, Martinez
    Francisco Javier, Carrera Hueso
    Carretero Rodolfo, Copado
    Jose Adolfo, Carrera Hueso
    Rodriguez Santiago, Martin
    Catalan Javier, Noguera
    ATENCION FARMACEUTICA, 2009, 11 (04): : 267 - 272
  • [28] Pneumocystis jirovecii pneumonia in kidney transplantation
    Goto, N.
    Oka, S.
    TRANSPLANT INFECTIOUS DISEASE, 2011, 13 (06) : 551 - 558
  • [29] Pneumocystis jirovecii pneumonia with an atypical granulomatous response after kidney transplantation
    Ramalho, J.
    Bacelar Marques, I. D.
    Aguirre, A. R.
    Pierrotti, L. C.
    de Paula, F. J.
    Nahas, W. C.
    David-Neto, E.
    TRANSPLANT INFECTIOUS DISEASE, 2014, 16 (02) : 315 - 319
  • [30] Epidemiology of Pneumocystis jirovecii Pneumonia in Venezuela
    Mercedes Panizo, Maria
    Ferrara, Giuseppe
    Garcia, Nataly
    Moreno, Xiomara
    Navas, Trina
    Calderon, Enrique
    Matos, Olga
    de La Horra, Carmen
    Friaza, Vicente
    Reviakina, Vera
    Dolande, Maribel
    Alarcon, Victor
    Maria Caceres, Ana
    CURRENT FUNGAL INFECTION REPORTS, 2020, 14 (01) : 21 - 28